Related Experiment Video

Updated: Jun 9, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous

Ilka Ott1, Stefanie Schulz, Julinda Mehilli

  • 11. Medizinische Klinik rechts der Isar, Munich, Germany. ott@dhm.mhn.de

Circulation. Cardiovascular Interventions
|August 26, 2010
PubMed

Insights

Erythropoietin (EPO) did not improve heart function or reduce infarct size in patients with acute ST-elevation myocardial infarction. The study suggests EPO may increase adverse clinical events in these patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Erythropoietin (EPO) shows promise in improving myocardial function in experimental models.
  • Its efficacy in human patients with acute ST-elevation myocardial infarction (STEMI) requires clinical investigation.

Purpose of the Study:

  • To evaluate the therapeutic value of erythropoietin in patients experiencing acute ST-elevation myocardial infarction.
  • To assess the impact of EPO on left ventricular ejection fraction and infarct size post-primary percutaneous coronary intervention.

Main Methods:

  • A randomized, double-blind study involving 138 patients with STEMI undergoing primary percutaneous coronary intervention.
  • Patients received either epoetin-β or a placebo immediately and at 24 and 48 hours post-procedure.
  • Primary endpoint was left ventricular ejection fraction (LVEF) at 6 months via MRI; secondary endpoints included infarct size and clinical adverse events.

Main Results:

  • No significant difference in LVEF at 6 months between the EPO group (52.0±9.1%) and placebo group (51.8±9.3%; P=0.92).
  • Infarct size and LVEF at 5 days also showed no significant differences between groups.
  • The cumulative incidence of adverse events (death, recurrent MI, stroke, revascularization) at 6 months was higher in the EPO group (13.2%) compared to placebo (5.7%), though not statistically significant (P=0.15).

Conclusions:

  • Erythropoietin treatment did not improve left ventricular function or reduce infarct size in STEMI patients treated with primary PCI.
  • The study indicates a potential increase in adverse clinical events with EPO use in this patient population.
  • Further research is needed to clarify the role and safety of EPO in acute myocardial infarction management.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...